Laurus Labs Limited - Asset Resilience Ratio
Laurus Labs Limited (LAURUSLABS) has an Asset Resilience Ratio of 0.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check LAURUSLABS strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Laurus Labs Limited's Asset Resilience Ratio has changed over time. See LAURUSLABS equity financing ratio to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Laurus Labs Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LAURUSLABS market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs633.80 Million | 0.67% |
| Short-term Investments | Rs63.40 Million | 0.07% |
| Total Liquid Assets | Rs697.20 Million | 0.74% |
Asset Resilience Insights
- Limited Liquidity: Laurus Labs Limited maintains only 0.74% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Laurus Labs Limited Industry Peers by Asset Resilience Ratio
Compare Laurus Labs Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Laurus Labs Limited (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Laurus Labs Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 0.57% | Rs528.20 Million ≈ $5.71 Million |
Rs93.36 Billion ≈ $1.01 Billion |
+0.33pp |
| 2024-03-31 | 0.23% | Rs195.50 Million ≈ $2.11 Million |
Rs83.87 Billion ≈ $907.03 Million |
-0.15pp |
| 2023-03-31 | 0.38% | Rs294.00 Million ≈ $3.18 Million |
Rs76.60 Billion ≈ $828.44 Million |
+0.06pp |
| 2022-03-31 | 0.32% | Rs222.40 Million ≈ $2.41 Million |
Rs69.68 Billion ≈ $753.57 Million |
-0.36pp |
| 2021-03-31 | 0.68% | Rs390.70 Million ≈ $4.23 Million |
Rs57.51 Billion ≈ $621.92 Million |
+0.68pp |
| 2020-03-31 | 0.00% | Rs880.00K ≈ $9.52K |
Rs37.50 Billion ≈ $405.58 Million |
+0.00pp |
| 2019-03-31 | 0.00% | Rs740.00K ≈ $8.00K |
Rs33.31 Billion ≈ $360.26 Million |
+2.21pp |
| 2018-03-31 | -2.20% | Rs-664.70 Million ≈ $-7.19 Million |
Rs30.17 Billion ≈ $326.25 Million |
+0.24pp |
| 2017-03-31 | -2.44% | Rs-648.62 Million ≈ $-7.01 Million |
Rs26.53 Billion ≈ $286.96 Million |
-2.09pp |
| 2016-03-31 | -0.35% | Rs-81.68 Million ≈ $-883.34K |
Rs23.03 Billion ≈ $249.07 Million |
+3.48pp |
| 2015-03-31 | -3.84% | Rs-706.89 Million ≈ $-7.64 Million |
Rs18.43 Billion ≈ $199.28 Million |
-- |
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It… Read more